Does Rallies show 13F holders for TSHA?

Yes. Rallies tracks hedge fund and 13F ownership data for TSHA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TSHA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TSHA. It does not provide personalized investment advice.

TSHA (Taysha Gene Therapies, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Taysha Gene Therapies, Inc. Common Stock (TSHA) is a publicly traded Healthcare sector company. As of May 21, 2026, TSHA trades at $5.20 with a market cap of $1.56B and a P/E ratio of -14.25. TSHA moved +5.69% today. Year to date, TSHA is +12.27%; over the trailing twelve months it is +87.37%. Its 52-week range spans $1.05 to $7.30. Analyst consensus is strong buy with an average price target of $12.10. Rallies surfaces TSHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TSHA stock?

Hedge funds tracked by Rallies that own TSHA include Polen Capital, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Taysha Gene Therapies, Inc. Common Stock.

TSHA Key Metrics

Key financial metrics for TSHA
Metric	Value
Price	$5.20
Market Cap	$1.56B
P/E Ratio	-14.25
EPS	$-0.38
Dividend Yield	0.00%
52-Week High	$7.30
52-Week Low	$1.05
Volume	14
Avg Volume	0
Revenue (TTM)	$7.47M
Net Income	$-129.88M
Gross Margin	0.00%

Top Hedge Funds Holding TSHA

Polen Capital holds 319.75K shares of TSHA, changed +104.20% as of Mar 31, 2026.
Panagora Asset holds 182.16K shares of TSHA, changed +1473.91% as of Mar 31, 2026.
Mangrove Partners holds 20.55K shares of TSHA, changed +0.00% as of Dec 31, 2025.

Latest TSHA News

Taysha Secures FDA BLA Alignment for TSHA-102 and Targets Q2 Dosing Completion — May 6, 2026
Taysha Gene Therapies to unveil 30-fold MeCP2 expression boost with TSHA-102 at ASGCT — Apr 27, 2026
Taysha Gene Therapies doses first patient in TSHA-102 pivotal trial, secures FDA BLA data alignment — Jan 6, 2026
First TSHA-102 Patient Dosed in REVEAL Pivotal Rett Syndrome Trial with Q2 2026 Completion — Jan 6, 2026
Taysha Gene Therapies on Track to Complete TSHA-102 REVEAL and ASPIRE Dosing by Q2 2026 — Mar 19, 2026

Recent TSHA Insider Trades

Nagendran Sukumar sold 200.00K (~$892.00K) on Apr 10, 2026.
Alam Kamran sold 1.66K (~$7.48K) on Feb 4, 2026.
Nagendran Sukumar sold 26.92K (~$124.09K) on Jan 26, 2026.

TSHA Analyst Consensus

10 analysts cover TSHA: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.10.

Common questions about TSHA

Who owns TSHA stock?: Hedge funds tracked by Rallies that own TSHA include Polen Capital, Panagora Asset, and Mangrove Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Taysha Gene Therapies, Inc. Common Stock.
Does Rallies show 13F holders for TSHA?: Yes. Rallies tracks hedge fund and 13F ownership data for TSHA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TSHA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TSHA. It does not provide personalized investment advice.